DeepMed Research

Carboxymethylcellulose

Generic Name: Carboxymethylcellulose

Brand Names: Leader Lubricant Eye Drops, Refresh Drops, Refresh Liquigel, Refresh Optive Advanced, Refresh Optive Extended Therapy, Retaine, Thera Tears, Theratears

Drug Type: Small Molecule

CAS Number: 9000-11-7

Unique Ingredient Identifier: 05JZI7B19X

Background: Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or thickener and emulsifier. It is also one of the most common viscous polymers used in artificial tears, and has shown to be effective in the treatment of aqueous tear-deficient dry eye symptoms and ocular surface staining . The viscous and mucoadhesive properties as well as its anionic charge allow prolonged retention time in the ocular surface . Sodium carboxymethylcellulose is the most commonly used salt.

Indication: Indicated for the symptomatic relief of burning, irritation and discomfort of the eyes due to dryness or exposure to wind or sun.

Associated Conditions: Dry Eyes, Ocular Irritation

Clinical Trials

The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients

Phase 4

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Hydroxypropylmethylcellulose
Drug: Carboxymethylcellulose

First Posted Date: 2011-01-20

Last Posted Date: 2012-07-18

Lead Sponsor: University of Campinas, Brazil

Target Recruit Count: 44

Registration Number: NCT01280110

Locations: 🇧🇷
Department of Ophthalmology, University of Campinas, Campinas, SP, Brazil

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

Phase 4

Completed

Conditions: Histamine Responsive Allergy Patients

Interventions: Drug: Bepreve
Drug: Refresh Tears

First Posted Date: 2010-05-24

Last Posted Date: 2010-07-08

Lead Sponsor: North Texas Institute for Clinical Trials

Target Recruit Count: 30

Registration Number: NCT01128556

Locations: 🇺🇸
North Texas Institute for Clinical Trials, Fort Worth, Texas, United States

Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Glycerin and Polysorbate 80 based artificial tear

First Posted Date: 2009-11-10

Last Posted Date: 2015-08-17

Lead Sponsor: Allergan

Target Recruit Count: 288

Registration Number: NCT01010282

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

Phase 4

Completed

Conditions: Dry Eye Syndromes
Keratoconjunctivitis Sicca

Interventions: Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)
Drug: sodium hyaluronate 0.18% (VISMED® Multi)

First Posted Date: 2009-10-01

Last Posted Date: 2011-09-21

Lead Sponsor: Allergan

Target Recruit Count: 82

Registration Number: NCT00987727

Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms

Phase 4

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: carboxymethylcellulose 0.5% +glycerin 0.9%
Drug: sodium hyaluronate 0.18%

First Posted Date: 2009-07-14

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 71

Registration Number: NCT00938704

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Glycerin and Polysorbate 80 based artificial tear

First Posted Date: 2009-07-03

Last Posted Date: 2015-08-26

Lead Sponsor: Allergan

Target Recruit Count: 47

Registration Number: NCT00932477

Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms

Phase 4

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®
Drug: Sodium hyaluronate

First Posted Date: 2008-09-29

Last Posted Date: 2013-11-19

Lead Sponsor: Allergan

Target Recruit Count: 50

Registration Number: NCT00761202

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

Phase 4

Terminated

Conditions: Blindness
Retinopathy of Prematurity
Retinal Detachment

Interventions: Drug: placebo
Drug: ACULAR
Drug: REFRESH TEARS

First Posted Date: 2008-03-13

Last Posted Date: 2020-12-08

Lead Sponsor: University of South Alabama

Target Recruit Count: 83

Registration Number: NCT00634972

Locations: 🇺🇸
Division of Neonatology, Children's & Women's Hospital, University of South Alabama, Mobile, Alabama, United States

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Carboxymethylcellulose and Glycerin based artificial tear
Drug: Carboxymethylcellulose

First Posted Date: 2007-10-16

Last Posted Date: 2011-12-14

Lead Sponsor: Allergan

Target Recruit Count: 228

Registration Number: NCT00544713

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Carboxymethylcellulose and Glycerin based artificial tear
Drug: Carboxymethylcellulose

First Posted Date: 2007-08-10

Last Posted Date: 2009-12-15

Lead Sponsor: Allergan

Target Recruit Count: 316

Registration Number: NCT00514852

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy